Form 4: Director Ron Squarer Trades ADC Therapeutics Shares

Director Ron Squarer reported transactions involving ADC Therapeutics SA common shares, including an annual grant of RSUs and withholding for tax obligations.

Summary

• Director Ron Squarer made several transactions related to ADC Therapeutics SA common shares.
• On June 1, 2026, Squarer received an annual grant of 45,000 restricted stock units (RSUs) under the Issuer's 2019 Equity Incentive Plan for his services as a Director. These RSUs vest one year from the grant date or at the 2027 Annual Meeting of Shareholders, provided Squarer continues his service.
• On June 3, 2026, 15,196 common shares were withheld by the Issuer to cover tax obligations arising from the vesting of previously granted restricted share units.
• Following these transactions, Squarer beneficially owns 123,431 common shares directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it details routine compensation and tax-related share transactions for a director, without indicating significant positive or negative performance indicators for the company.

Positives

• Director Ron Squarer received an annual grant of 45,000 RSUs, indicating continued compensation and incentive for service.
• The RSUs vest over time, aligning the director's interests with the company's long-term performance.
• The company is managing tax withholding obligations efficiently through share withholding.

Negatives

• 15,196 common shares were withheld for tax purposes, reducing the net number of shares received by the director.

Risks

• The vesting of RSUs is contingent upon the Reporting Person's continued service to the Issuer, implying a risk of forfeiture if service is terminated.
• The value of the RSUs is subject to the market performance of ADC Therapeutics SA's common stock.

Future Outlook

The RSUs granted to Director Ron Squarer are subject to vesting conditions, with potential vesting occurring on the earlier of one year from the grant date or the date of the 2027 Annual Meeting of Shareholders, contingent upon his continued service.

Management Comments

• The annual grant of restricted stock units (RSUs) is made under the Issuer's 2019 Equity Incentive Plan for service as a Director.
• The RSUs vest on the earlier of (i) one year from the grant date or (ii) the date of the 2027 Annual Meeting of Shareholders, subject to the Reporting Person's continued service to the Issuer.
• Each RSU represents a contingent right to receive one share of the Issuer's common stock.
• Common Shares were withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted.

Industry Context

StockSavvy.ai notes that the reporting of equity grants and subsequent tax withholding for directors is a standard practice within the biotechnology and pharmaceutical sectors, reflecting common compensation structures designed to retain key leadership and align their interests with shareholder value.

Related Party Transactions

• The grant of restricted stock units to Director Ron Squarer is a related party transaction, as it involves compensation for services rendered by a director.

Stakeholder Impact

• Shareholders: The RSU grant represents a form of compensation, which impacts dilution. The tax withholding reduces the net shares received by the director.
• Employees: The filing does not directly impact employees, but it reflects the company's compensation practices for its board.
• Management: The filing details compensation for a board member, which is a standard governance practice.

Next Steps

• Director Ron Squarer's RSUs will vest on the earlier of one year from the grant date (June 1, 2027) or the date of the 2027 Annual Meeting of Shareholders, provided he continues his service.
• Future tax withholding obligations related to equity compensation will be managed by the Issuer.

Key Dates

Keywords

ADC Therapeutics SA, ADCT, Form 4, SEC Filing, Director Compensation, Restricted Stock Units, RSUs, Beneficial Ownership, Equity Incentive Plan, Tax Withholding